Predict your next investment

SOFTWARE (NON-INTERNET/MOBILE) | Stealth Mode

See what CB Insights has to offer

Founded Year

2016

Stage

Unattributed | Alive

Total Raised

$800K

Last Raised

$800K | 2 yrs ago

About DOHME

DOHME is a New York, New York-based software company operating in stealth.

DOHME Headquarter Location

527 East 72nd Street Suite 2A

New York, New York, 10021,

United States

Latest DOHME News

13:30 ET Ocular Hypertension Market to Witness Robust Expansion at a 3.82% CAGR During the Study Period [2018-2030], Evaluates D...

Sep 23, 2021

The emerging therapies such as DE-117 (Santen Pharmaceutical); sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics), and Nyxol (Ocuphire Pharma) are compelling treatments and are expected to change the Ocular Hypertension market scenario in the upcoming years. News provided by Share this article Share this article LAS VEGAS, Sept. 23, 2021 /PRNewswire/ -- DelveInsight's " Ocular Hypertension Market " report provides a thorough comprehension of the Ocular Hypertension historical and forecasted epidemiology and the Ocular Hypertension market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Ocular Hypertension market report also proffers an analysis of the current Ocular Hypertension treatment algorithm/practice, market drivers, market barriers, and unmet medical needs. Several key pharmaceutical companies, including Novartis, Bausch and Lomb Incorporated, Merck Sharp and Dohme, Aerie Pharmaceuticals, Santen Pharmaceutical, Nicox Ophthalmics, and others, are developing novel products to improve the Ocular Hypertension treatment outlook. In March 2020, Allergan announced that the US FDA had approved Durysta (bimatoprost implant), making it the first intracameral, biodegradable sustained-release implant. The Ocular Hypertension market is undergoing a continuous change in the coming years, owing to the rising prevalent population, increased patient awareness, and improved diagnostic methods. Several approved therapies such as Durysta, Alphagan-P, Rhopressa, and others will drive the current Ocular Hypertension therapeutic landscape in the US and is estimated to increase by 2030. Ocular Hypertension is complex and has a polygenic basis resulting from a combined effect of various common gene variants, each of which has a small effect on the disease. Genome-wide association analyses have recognized several loci associated with glaucoma risk factors such as IOP, vertical cup-disc ratio, and central corneal thickness. In the last decade, significant efforts have been made to develop new products that use novel approaches to address the unmet needs associated with Ocular Hypertension. Advancements are seen within currently used eye drop classes such as prostaglandin analogs, Rho-kinase inhibitors, and nitric oxide donors, while there are also new drug classes, such as tyrosine-protein kinase activators. Most developing drugs are topical drop formulations, with a number already having entered Phase III trials. Ocular Hypertension is a term used to describe intraocular pressure (IOP) greater than 21 mm Hg in one or both eyes without clinical evidence of optic nerve damage, visual field defect. DelveInsight estimates that the total Ocular Hypertension prevalent cases  were 20,817,647 cases in the 7MM in 2020. It was also noted that females are affected more than males. The Ocular Hypertension Market Analysis Report  provides historical as well as forecasted epidemiological analysis segmented into:  Total Prevalent Cases of Ocular Hypertension  Gender-specific Prevalence of Ocular Hypertension  Age-specific Prevalence of Ocular Hypertension  Treated Cases of Ocular Hypertension  The Ocular Hypertension market has been categorized based on different classes of therapies available for the treatment. These include prostaglandin analogs, beta-blockers, alpha-agonists, carbonic anhydrase inhibitors, alpha agonists, rho kinase inhibitors, and combination therapies. Prostaglandin analogs (PGAs) are recommended as the first-choice treatment for Primary open-angle glaucoma (POAG) because of their efficacy, limited systemic side effects, and once-daily dosing. Travoprost, Vyzulta, Zioptan are the commonly prescribed prostaglandin analogs. Before the entry of prostaglandins into the market, beta-blockers were quite well-known and popular for glaucoma management. Combination therapies account for the second-highest revenue-generating class of therapy after PGAs. Combining agents of different classes with a different mechanism of action (MoA) is associated with superior IOP-lowering efficacy than each component used alone. Fixed combinations eye drops in Europe include prostaglandin analogs and β-blockers, carbonic anhydrase inhibitors and β-blockers, α-2 adrenergic agonists and β-blockers, carbonic anhydrase inhibitor and α-2 adrenergic agonists, and β -blockers. Carbonic Anhydrase Inhibitors like dorzolamide and Trusopt are favored over oral agents because of their greater site-specificity and markedly fewer systemic side effects. In the Ocular Hypertension emerging scenario, several companies are developing therapies for IOP that employ rho kinase inhibitors, nitric oxide (NO)-donating prostaglandin analogs, ROCK inhibitors, and others. Pharmaceutical companies like Santen Pharmaceuticals, Allergan, Sun Pharma Advanced Research Company (SPARC) Limited, Laboratorios Sophia S.A de C.V., Nicox Ophthalmics, and Nicox Ophthalmics are developing products with the potential to change the Ocular Hypertension treatment landscape. The pharmaceutical products of these companies are currently in the late and mid-clinical development stages. The emerging therapies such as DE-117 (Santen Pharmaceutical); PDP-716 (Sun Pharma); sepetaprost (DE-126/ONO-9054: Santen/Ono Pharmaceutical); NCX 470 (Nicox Ophthalmics), and Nyxol (Ocuphire Pharma) are effective treatments. These drug candidates have shown highly promising results, and DelveInsight's analysts have anticipated that completion of clinical development and launch of these products might increase the Ocular Hypertension market share of these companies, in addition to the availability of better management practices for Ocular Hypertension patients. Ocular Hypertension Market size shall increase owing to recent advances in therapy, particularly intravitreal administration of anti-angiogenic agents, which have opened new therapeutic perspectives. Also, a considerable amount of attention is being given to imaging biomarkers to fulfill the unmet need for better Ocular Hypertension diagnosis. It has been a promising development over the previous decade. The launch of such biomarkers would lead to a significant boost during the forecast years. Nevertheless, the growth of the Ocular Hypertension Market might be impeded by the lack of clarity about the disease pathophysiology, dearth of accurate diagnosis, and a few effective treatment options available. Moreover, there is an unmet need for a wider variety of such surgical procedures to provide long-term IOP-lowering effects, and in more complex cases such as angle-closure glaucoma and secondary diseases. Study Period: 3-year historical and 10-year forecasted analysis (2018-2030). Ocular Hypertension Markets Segmentation: By Geographies and By Ocular Hypertension Therapies (Historical and Forecasted, Current and Upcoming)  Dominant Market Companies investigating its candidates for Ocular Hypertension: Novartis, Bausch and Lomb Incorporated, Merck Sharp and Dohme, Aerie Pharmaceuticals, Santen Pharmaceutical, Nicox Ophthalmics, and several others. Analysis: Comparative and conjoint analysis of emerging therapies. Case Studies DelveInsight's 'Bradycardia Treatment Devices -Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Bradycardia Treatment Devices. Key companies working in this domain are Abbott Laboratories, Biotronik, Boston Scientific, Lepu Medical, Livanova, Medico, Medtronic, Oscor, Osypka Medical, and others. DelveInsight's 'Anastomotic Leak Devices -Market Insights, Competitive Landscape and Market Forecast - 2026' report delivers an in-depth understanding of Anastomotic Leak Devices. Key companies working in this domain are Baxter International Inc. (Synovis Micro Companies Alliance), Medtronic PLC Cryolife, Inc., Getinge AB, Ethicon US LLC. (Johnson & Johnson), Peter Surgical, Becton, and others. Browse Blog Posts  Explore Cost-effectiveness, Advanced Technology, Rising Demand that Pushes the Insulin Delivery Devices Market Read FemTech Market : With 100+ Startups in the domain, Women Healthcare is Witnessing a Huge Upliftment DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides  Business Consulting Services  with a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach. Contact Us:

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.